References
- International Organization for Standardization (ISO). Medical laboratories – particular requirements for quality and competence. ISO 15189:2012.
- Topic E, Nikolac N, Panteghini M, et al. How to assess the quality of your analytical method? Clin Chem Lab Med. 2015;53:1707–1718.
- Nichols JH. Verification of method performance for clinical laboratories. Adv Clin Chem. 2009;47:121–137.
- Antonelli G, Sciacovelli L, Aita A, et al. The pathway for introducing novel examination procedures in routine practice in accordance with ISO 15189:2012: 17-Hydroxy progesterone, dehydroepiandrosterone sulphate and vitamin D as examples. Ann Clin Biochem. 2019;56:548–555.
- Debeljak Ž, Marković I, Pavela J, et al. Analytical bias of automated immunoassays for six serum steroid hormones assessed by LC-MS/MS. Biochem Med. 2020;30:030701.
- Taylor AE, Keevil B, Huhtaniemi IT. Mass spectrometry and immunoassay: how to measure steroid hormones today and tomorrow. Eur J Endocrinol. 2015;173:D1–D12.
- Clinical and Laboratory Standards Institute (CLSI). User verification of performance for precision and trueness; approved guideline. 2nd ed. Wayne (PA): CLSI; 2005. EP15-A2.
- Garzon NJ, Minchinela J, et al. The EFLM Biological Variation Database. Available from: https://biologicalvariation.eu/
- Desirable specifications for total error, imprecision, and bias, derived from intra- and inter-individual biologic variation. Available from: https://www.westgard.com/biodatabase1.htm
- Radišić Biljak V, Đuras A, Čičak H, et al. Women in sports: the applicability of reference intervals for 6 commercially available testosterone immunoassays (HemSter Study). Clin Biochem. 2020;84:55–62.
- Total 25-hydroxyvitamin D. 510(k) Substantial equivalence determination decision summary (k162840). Available from: https://www.accessdata.fda.gov/cdrh_docs/reviews/K162840.pdf
- MAGLUMI 2000 25-OH Vitamin D. 510(k) Substantial equivalence determination decision summary (k191499). Available from: https://www.accessdata.fda.gov/cdrh_docs/reviews/K191499.pdf
- Wieringa GE, Sturgeon CM, Trainer PJ. The harmonisation of growth hormone measurements: taking the next steps. Clin Chim Acta. 2014;432:68–71.
- Galluzzi F, Quaranta MR, Salti R, et al. Reference values for IGF-I serum concentrations: comparison of six immunoassays. J Clin Endocrinol Metab. 2016;101:3450–3458.
- Cosma C, Padoan A, Plebani M. Automated Mindray CL-1200i chemiluminescent assays of renin and aldosterone for the diagnosis of primary aldosteronism. Clin Chem Lab Med. 2021.
- Clinical and Laboratory Standards Institute (CLSI). Defining, establishing, and verifying reference intervals in the clinical laboratory; approved Guideline. 3rd ed. Wayne (PA):CLSI; 2008. EP28-A3c.
- Alshahrani F, Aljohani N. Vitamin D: deficiency, sufficiency and toxicity. Nutrients. 2013;5:3605–3616.
- Friedrich N, Wolthers OD, Arafat AM, et al. Age- and sex-specific reference intervals across life span for insulin-like growth factor binding protein 3 (IGFBP-3) and the IGF-I to IGFBP-3 ratio measured by new automated chemiluminescence assays. J Clin Endocrinol Metab. 2014;99:1675–1686.
- Soldin OP, Sharma H, Husted L, et al. Pediatric reference intervals for aldosterone, 17alpha-hydroxyprogesterone, dehydroepiandrosterone, testosterone and 25-hydroxy vitamin D3 using tandem mass spectrometry. Clin Biochem. 2009;42:823–827.
- Adeli K, Higgins V, Trajcevski K, et al. The Canadian laboratory initiative on pediatric reference intervals: a CALIPER white paper. Crit Rev Clin Lab Sci. 2017;54:358–413.